Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.47 |
| ▸ | TXK | P42681 | 12/20 | 0.47 |
| ▸ | BTK | Q06187 | 12/20 | 0.47 |
| ▸ | ITK | Q08881 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29932902 | 1.00 | JAK3 (0.47) | JAK3TXKBTKITK | |
| SCHEMBL5655948 | 0.89 | JAK3 (0.48) | JAK3TXKBTKITK | |
| SCHEMBL20161423 | 0.87 | JAK3 (0.47) | JAK3TXKBTKITK | |
| SCHEMBL20161503 | 0.86 | GABRP (0.44) | JAK3TXKBTKITK | |
| SCHEMBL29932845 | 0.86 | GABRP (0.44) | JAK3TXKBTKITK | |
| SCHEMBL20162005 | 0.83 | JAK3 (0.39) | JAK3TXKBTKITK | |
| SCHEMBL14460569 | 0.82 | ITK (0.70) | JAK3TXKBTKITK | |
| SCHEMBL30291400 | 0.82 | ITK (0.70) | JAK3TXKBTKITK | |
| SCHEMBL14460588 | 0.81 | ITK (0.60) | JAK3TXKBTKITK | |
| SCHEMBL20161728 | 0.80 | TXK (0.45) | JAK3TXKBTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220363676-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. | 2022-11-17 | — | — | US | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-6956045-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-18 | — | — | US | disclosed |
| US-6953795-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-06-10 | — | — | US | disclosed |
| US-20040077695-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JO I C (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040067989-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-04-08 | — | — | US | disclosed |
| US-6706717-B2 | ANTICANCER AGENTS; IMMUNOLOGY DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| EP-1347971-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| WO-2002050071-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | JAK3 695/4885TXK 47/4885BTK 672/4885 |
| US-20040077695-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | JAK3 61/4885TXK 55/4885BTK 4/4885 |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | JAK3 61/4885TXK 55/4885BTK 4/4885 |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | JAK3 341/4885TXK 201/4885BTK 398/4885 |
| US-20040067989-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | JAK3 61/4885TXK 55/4885BTK 4/4885 |
| US-20220363676-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | IL2, NFATC1, IL2RA | JAK3 341/4885TXK 201/4885BTK 398/4885 |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | JAK3 61/4885TXK 55/4885BTK 4/4885 |
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | IL2, NFATC1, IL2RA | JAK3 341/4885TXK 201/4885BTK 398/4885 |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | JAK3 61/4885TXK 55/4885BTK 4/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | JAK3 341/4885TXK 201/4885BTK 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.